MyMD Pharmaceuticals is a clinical-stage pharmaceutical company committed to extending a healthy lifespan through two therapeutic platforms, MYMD-1 and Supera-CBD. MyMD came to Antenna Group for a new website ahead of its reverse merger with Akers Biosciences and plans to go public. The website would support MyMD’s ongoing PR efforts and provide information to shareholders, new investors and the media.
Antenna Group’s digital and ecosystem experts worked with MyMD on new messaging for the merged companies alongside a website strategy, content, design and development to to share the potential of its scientific research and promising drug therapies in a way that was engaging and easy to understand. The website showcases MyMD’s pipeline of drug candidates and recent research while engaging site visitors and investors through thought leadership content and the ability to subscribe to MyMD.com for updates.